Strategic alliances and collaborations are an important component of Quanterix’s overall business strategy. Quanterix is actively working with commercial partners to develop and validate bioassays that address unmet needs in life science research and clinical diagnostics.

Quanterix headquarters, Lexington MA

Quanterix is also partnering with clinical investigators to improve the performance of existing tests that may lead to new clinical utility in a variety of applications areas, and life science researchers to translate proteomic and expression array-based research into serum-based tests. With a 1000-fold sensitivity advantage, Simoa can potentially measure hundreds to thousands of new biomarkers, creating a broad opportunity for validation of novel tests that may have diagnostic value.

Because the Simoa HD-1 Analyzer is not yet commercially available, Quanterix is collaborating with investigators to develop, optimize and validate tests within its state-of-the-art facility located in Lexington, MA. Quanterix will continue to establish partnerships with leading clinical and academic researchers to enable development of new assays for interesting biomarkers that could potentially benefit from increased sensitivity and precision.

We encourage you to contact us if your current immunoassay analysis of biomarkers, proteins or small molecules is hindered by insufficient limits of detection and quantification.

David Hanlon, Ph.D.
Director, Business Development and Strategic Collaborations
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: 617-301-9430